** Shares of Amgen AMGN.O rise nearly 1% to $286.50 in aftermarket trading
** Drugmaker reports Q1 adj. profit per share of $4.90, beating estimates of $4.30
** Company's quarterly revenue up 9% to $8.1 billion
** Says U.S. FDA has lifted its clinical hold on an early-stage trial of an experimental weight-loss drug known as AMG 513
** Reiterates annual adj. profit per share to be between $20 and $21.20; 2025 revenue to be in the range of $34.3 billion to $35.7 billion
** Adds 2025 projection includes the estimated impact of implemented tariffs, but does not account for any tariff that could be implemented in the future, including potential sector-specific ones
** Stock rose 9% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。